President Joe Biden’s failure to name someone to lead the Food and Drug Administration, more than 10 months after the election, has flummoxed public health experts who say it’s baffling for the agency to be without a permanent leader during a national health crisis.
The pandemic has taxed the FDA, an 18,000-person agency whose chiefs have traditionally received bipartisan backing during the Senate confirmation process. Many leaders in public health, industry and consumer groups agree that Biden’s foot-dragging on finding a new director has demoralized the staff and sent the wrong message about the agency’s importance, even as the toll of covid-19 mounts, with an average of 130,000 new cases and 1,500 deaths daily, according to the Centers for Disease Control and Prevention.
It’s a tough job in normal times, observers say, and at the moment may be the worst top job in Washington. At the heart of the tension is finding a nominee who balances the agency’s dual responsibilities of protecting public health while also working with the drug, medical device and other industries to approve products and treatments for market. Meanwhile, the agency has been mired in controversies related to drug approvals and covid vaccines, and discord over decisions has spilled into public view.
FDA commissioner is a “particularly rough job in wartime,” said Steven Grossman, executive director of the Alliance for a Stronger FDA, an outside organization consisting of industry, research and other groups, which pushes for Congress to increase agency funding. “It is a much more difficult post to fill than it appears to the eye.”
Dr. Janet Woodcock, an agency veteran of three decades, has for months led as acting commissioner. She commands broad respect. But her perceived closeness to the drug industry, particularly with respect to the agency’s role in the opioid crisis, led some Senate Democrats to come out against her official assumption of the role. Biden would need all Democrats on board or some Republican senators to back his choice to get the votes for confirmation.
In December, Biden announced other top health appointees who would helm his pandemic response, including Health and Human Services Secretary Xavier Becerra, Surgeon General Vivek Murthy and CDC Director Rochelle Walensky. HHS oversees the FDA — as it does the office of the Surgeon General, the CDC and the National Institutes of Health.
But still no sign of an FDA nomination. Biden officials reportedly considered multiple potential candidates throughout the spring, including Woodcock; former top FDA official and Maryland health secretary Joshua Sharfstein; former FDA official Michelle McMurry-Heath; and Scripps Research Translational Institute director Dr. Eric Topol (who confirmed to KHN he wasn’t interested). Then the process seemed to deadlock.
“People are just flabbergasted,” said Dr. John Whyte, chief medical officer of WebMD and former FDA official. “We don’t even have rumors of viable candidates.”
Many of the agency’s other critical responsibilities require sustained leadership even as the FDA urgently vets covid treatments, tests and vaccines, according to people in public health, the health care industry and consumer groups. The FDA oversees much of the nation’s food supply and the regulation of tobacco products, and reviews everything from stents and catheters to cancer drugs.
Long-term decisions on tobacco regulation can’t wait, said Matthew Myers, president of the Campaign for Tobacco-Free Kids, which has pushed the FDA to move quickly to implement a ban on menthol cigarettes — something it announced in April — and decide which e-cigarettes can stay on the market. This month the agency punted on whether it would ban the sale of e-cigarettes from several major companies, including Juul, the largest maker of such products.
“What the FDA does over the next weeks or months with regard to e-cigarettes will determine whether we have a decades-long youth e-cigarette epidemic or whether we reverse it now,” Myers said. “Waiting for a new commissioner is not an option.”
He and others conceded that, regardless of qualifications, an acting commissioner’s ability to set priorities is diminished. That adds to anxiety about a leadership vacuum, even though few doubt Woodcock’s expertise.
“One significant disadvantage to being ‘acting’ is there is no time frame of how long that individual will be in that position,” said Dr. Andrew von Eschenbach, FDA commissioner in the George W. Bush administration. As important work is executed, “there is no certainty” how long an acting leader is “going to be there” to see it through, he said. “That’s an instability that is very, very difficult to deal with.”
For agency staffers, it stings to see other physicians in the Biden administration speak publicly on issues squarely in the agency’s purview, said Stacy Cline Amin, a partner at law firm Morrison & Foerster and former chief counsel of the agency.
“It’s been a morale hit for FDA,” she said.
Under federal law, Woodcock can serve as acting commissioner until mid-November unless Biden nominates a permanent commissioner, in which case she can remain until that person is confirmed by the Senate.
“People are anxious,” said Ellen Sigal, founder of the influential nonprofit Friends of Cancer Research, which receives funding from the pharmaceutical industry and supported Woodcock for the job. “Is it going to be someone that knows the agency? Is it going to be someone that people really respect and really want to work with?”
The FDA is overwhelmingly run by career scientists whose jobs don’t depend on who wins the White House. Any Senate-confirmed leader largely defers to the scientists who run FDA divisions to make decisions on products, according to former officials and experts with knowledge of the agency’s inner workings. For example, an FDA spokesperson said Woodcock was not involved in the controversial decision to approve Aduhelm, a costly Alzheimer’s drug manufactured by Biogen that went to market even though experts say there’s little evidence it works. But in July, the lingering controversy led Woodcock to ask the HHS Office of Inspector General to “conduct an independent review and assessment of interactions between representatives of Biogen and FDA during the process that led to the approval of Aduhelm.”
A leader appointed by the president and confirmed by the Senate has clout in setting priorities, hiring staff and making long-term decisions.
“The commissioner has obviously tremendous influence … not on a product-by-product basis but what the philosophy is,” related to the regulatory process, said Scott Whitaker, president and CEO of AdvaMed, which lobbies for the medical device industry. The expressed paradigm “can impact how you think about developing products.”
Others said Biden’s speed in announcing a nominee is less important than selecting the right one, a calculation that’s especially fraught given the agency’s recent controversies.
Chief among them was the criticism from several scientists after the Biden administration announced a plan for widespread covid “booster” shots beginning Sept. 20, well before agency scientists had finished necessary reviews. Woodcock had signed onto an HHS statement announcing the plan, but some experts said the proposal came too far ahead of the science and unfairly jammed her staff. Two veteran FDA officials who have announced their retirements were part of an international group of scientists that published an essay in The Lancet questioning whether the general public needed additional vaccine doses at this time.
The FDA was expected to authorize booster shots for high-risk patients and those 65 and older, following the recommendation Friday of an advisory panel that overwhelmingly rejected the administration’s initial plan to offer extra shots for the general population, citing a need for additional research.
The White House didn’t respond to questions about why Biden hasn’t nominated someone as FDA commissioner or set a timeline for doing so.
“If it takes a little longer to get the right person who’s going to be more aligned in protecting public health and represent interests of the public, as opposed to the interest of industry, which is what the case has been for many years under Dr. Woodcock, then it may be worth the wait,” said Dr. Michael Carome, director of the health research group at Public Citizen, a liberal advocacy group that opposed Woodcock’s nomination. The FDA referred a request for comment to the White House, which didn’t respond.
Sigal sees it differently.
“FDA approves drugs, and they have to work with industry,” she said. “The fact that you work with industry on drug development or on diagnostics with developers, or you work with people that are manufacturing food, with manufacturers or whatever — it’s what the agency does.”
Some elements may be removed from this article due to republishing restrictions. If you have questions about available photos or other content, please contact email@example.com.